MX2008011665A - Diagnóstico y pronóstico de los estados patológicos asociados a la dipeptidil-peptidasa. - Google Patents
Diagnóstico y pronóstico de los estados patológicos asociados a la dipeptidil-peptidasa.Info
- Publication number
- MX2008011665A MX2008011665A MX2008011665A MX2008011665A MX2008011665A MX 2008011665 A MX2008011665 A MX 2008011665A MX 2008011665 A MX2008011665 A MX 2008011665A MX 2008011665 A MX2008011665 A MX 2008011665A MX 2008011665 A MX2008011665 A MX 2008011665A
- Authority
- MX
- Mexico
- Prior art keywords
- dpp
- parameter
- measured
- activity
- isoforms
- Prior art date
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 83
- 201000010099 disease Diseases 0.000 title claims abstract description 56
- 238000003745 diagnosis Methods 0.000 title claims abstract description 21
- 238000004393 prognosis Methods 0.000 title claims abstract description 16
- 102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 title claims description 170
- 108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 title claims description 170
- 238000000034 method Methods 0.000 claims abstract description 113
- 238000005259 measurement Methods 0.000 claims abstract description 59
- 239000013610 patient sample Substances 0.000 claims abstract description 22
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 claims description 180
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims description 170
- 108010029485 Protein Isoforms Proteins 0.000 claims description 163
- 102000001708 Protein Isoforms Human genes 0.000 claims description 163
- 230000000694 effects Effects 0.000 claims description 148
- 206010012601 diabetes mellitus Diseases 0.000 claims description 40
- 230000001575 pathological effect Effects 0.000 claims description 34
- 238000003556 assay Methods 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 27
- 230000014509 gene expression Effects 0.000 claims description 27
- 210000002381 plasma Anatomy 0.000 claims description 25
- 230000004481 post-translational protein modification Effects 0.000 claims description 24
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 20
- 238000000926 separation method Methods 0.000 claims description 19
- 210000004369 blood Anatomy 0.000 claims description 15
- 239000008280 blood Substances 0.000 claims description 15
- 238000001962 electrophoresis Methods 0.000 claims description 15
- 239000000758 substrate Substances 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 102000004856 Lectins Human genes 0.000 claims description 10
- 108090001090 Lectins Proteins 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 239000002523 lectin Substances 0.000 claims description 10
- 235000001014 amino acid Nutrition 0.000 claims description 8
- 210000001519 tissue Anatomy 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 7
- 230000007062 hydrolysis Effects 0.000 claims description 7
- 238000006460 hydrolysis reaction Methods 0.000 claims description 7
- 230000004060 metabolic process Effects 0.000 claims description 7
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 6
- 210000002966 serum Anatomy 0.000 claims description 6
- 238000012545 processing Methods 0.000 claims description 5
- 208000036142 Viral infection Diseases 0.000 claims description 4
- 238000002955 isolation Methods 0.000 claims description 4
- 210000001179 synovial fluid Anatomy 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 239000004475 Arginine Chemical group 0.000 claims description 3
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 3
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical group C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 3
- 235000004279 alanine Nutrition 0.000 claims description 3
- 210000004381 amniotic fluid Anatomy 0.000 claims description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 3
- 201000011510 cancer Diseases 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 238000000265 homogenisation Methods 0.000 claims description 3
- 210000003097 mucus Anatomy 0.000 claims description 3
- 210000003296 saliva Anatomy 0.000 claims description 3
- 210000000582 semen Anatomy 0.000 claims description 3
- 210000001138 tear Anatomy 0.000 claims description 3
- 210000002700 urine Anatomy 0.000 claims description 3
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 2
- 238000004891 communication Methods 0.000 claims 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 108030006877 Dipeptidyl-dipeptidases Proteins 0.000 abstract 1
- 239000000523 sample Substances 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 25
- 238000001997 free-flow electrophoresis Methods 0.000 description 23
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 238000001155 isoelectric focusing Methods 0.000 description 17
- 238000001514 detection method Methods 0.000 description 13
- 108090000765 processed proteins & peptides Proteins 0.000 description 13
- 102000035195 Peptidases Human genes 0.000 description 12
- 108091005804 Peptidases Proteins 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 230000002596 correlated effect Effects 0.000 description 9
- 101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 8
- 239000000499 gel Substances 0.000 description 8
- 239000011159 matrix material Substances 0.000 description 8
- 208000030159 metabolic disease Diseases 0.000 description 8
- 102000004196 processed proteins & peptides Human genes 0.000 description 8
- 235000019833 protease Nutrition 0.000 description 8
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 7
- 230000001186 cumulative effect Effects 0.000 description 7
- 230000006870 function Effects 0.000 description 7
- 230000002068 genetic effect Effects 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 102100028626 4-hydroxyphenylpyruvate dioxygenase Human genes 0.000 description 6
- 108010016626 Dipeptides Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- 210000001744 T-lymphocyte Anatomy 0.000 description 6
- 230000003197 catalytic effect Effects 0.000 description 6
- 230000002255 enzymatic effect Effects 0.000 description 6
- 229920002469 poly(p-dioxane) polymer Polymers 0.000 description 6
- 108010044467 Isoenzymes Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000033228 biological regulation Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 102100029921 Dipeptidyl peptidase 1 Human genes 0.000 description 4
- 102100020751 Dipeptidyl peptidase 2 Human genes 0.000 description 4
- 102100020750 Dipeptidyl peptidase 3 Human genes 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 4
- 108010054147 Hemoglobins Proteins 0.000 description 4
- 239000004365 Protease Substances 0.000 description 4
- 101000886298 Pseudoxanthomonas mexicana Dipeptidyl aminopeptidase 4 Proteins 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 230000008030 elimination Effects 0.000 description 4
- 238000003379 elimination reaction Methods 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004400 Aminopeptidases Human genes 0.000 description 3
- 108090000915 Aminopeptidases Proteins 0.000 description 3
- 101710087078 Dipeptidyl peptidase 1 Proteins 0.000 description 3
- 101710087084 Dipeptidyl peptidase 2 Proteins 0.000 description 3
- 108050001925 Dipeptidyl-peptidase 3 Proteins 0.000 description 3
- 101100322030 Drosophila melanogaster Abl gene Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 230000031018 biological processes and functions Effects 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000012875 competitive assay Methods 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- -1 glycyl-prolyl Chemical group 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000011486 lichen planus Diseases 0.000 description 3
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 238000002798 spectrophotometry method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- JBNOVHJXQSHGRL-UHFFFAOYSA-N 7-amino-4-(trifluoromethyl)coumarin Chemical compound FC(F)(F)C1=CC(=O)OC2=CC(N)=CC=C21 JBNOVHJXQSHGRL-UHFFFAOYSA-N 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 102000055025 Adenosine deaminases Human genes 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090001081 Dipeptidases Proteins 0.000 description 2
- 102000004860 Dipeptidases Human genes 0.000 description 2
- 102100036966 Dipeptidyl aminopeptidase-like protein 6 Human genes 0.000 description 2
- 102100036968 Dipeptidyl peptidase 8 Human genes 0.000 description 2
- 102100036969 Dipeptidyl peptidase 9 Human genes 0.000 description 2
- 102400000322 Glucagon-like peptide 1 Human genes 0.000 description 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000804935 Homo sapiens Dipeptidyl aminopeptidase-like protein 6 Proteins 0.000 description 2
- 101000804947 Homo sapiens Dipeptidyl peptidase 8 Proteins 0.000 description 2
- 101000804945 Homo sapiens Dipeptidyl peptidase 9 Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108090000189 Neuropeptides Proteins 0.000 description 2
- 102100023832 Prolyl endopeptidase FAP Human genes 0.000 description 2
- 101710135670 Putative Xaa-Pro dipeptidyl-peptidase Proteins 0.000 description 2
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 2
- 102100039662 Xaa-Pro dipeptidase Human genes 0.000 description 2
- 101710143531 Xaa-Pro dipeptidyl-peptidase Proteins 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229940001468 citrate Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000006911 enzymatic reaction Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- KZNQNBZMBZJQJO-YFKPBYRVSA-N glyclproline Chemical compound NCC(=O)N1CCC[C@H]1C(O)=O KZNQNBZMBZJQJO-YFKPBYRVSA-N 0.000 description 2
- 108010077515 glycylproline Proteins 0.000 description 2
- 102000045598 human DPP4 Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000002132 lysosomal effect Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108010066823 proline dipeptidase Proteins 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 238000007693 zone electrophoresis Methods 0.000 description 2
- UTDVHCQTKWTQEA-UHFFFAOYSA-N 1-(2-aminoacetyl)-n-(4-methyl-2-oxochromen-7-yl)pyrrolidine-2-carboxamide Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1NC(=O)C1CCCN1C(=O)CN UTDVHCQTKWTQEA-UHFFFAOYSA-N 0.000 description 1
- 241000208140 Acer Species 0.000 description 1
- 206010001557 Albinism Diseases 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 241000726096 Aratinga Species 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000023328 Basedow disease Diseases 0.000 description 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 108010012236 Chemokines Proteins 0.000 description 1
- 102000019034 Chemokines Human genes 0.000 description 1
- 208000006332 Choriocarcinoma Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 108700036514 EC 3.4.14.1 Proteins 0.000 description 1
- 108700036515 EC 3.4.14.3 Proteins 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 208000010055 Globoid Cell Leukodystrophy Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 101710088083 Glomulin Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 208000034596 Gyrate atrophy of choroid and retina Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 description 1
- 108700028608 Histidinemia Proteins 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101100152799 Homo sapiens TFDP3 gene Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000028226 Krabbe disease Diseases 0.000 description 1
- 208000006136 Leigh Disease Diseases 0.000 description 1
- 208000017507 Leigh syndrome Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010058799 Mitochondrial encephalomyopathy Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 1
- 208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000005890 Neuroma Diseases 0.000 description 1
- 102000003797 Neuropeptides Human genes 0.000 description 1
- 208000014060 Niemann-Pick disease Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000713112 Orthobunyavirus Species 0.000 description 1
- 241000702244 Orthoreovirus Species 0.000 description 1
- 101710160107 Outer membrane protein A Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 208000007452 Plasmacytoma Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101000908388 Rattus norvegicus Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 241000501499 Sialis Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 208000000389 T-cell leukemia Diseases 0.000 description 1
- 208000028530 T-cell lymphoblastic leukemia/lymphoma Diseases 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 102100030138 Thymus-specific serine protease Human genes 0.000 description 1
- 101710140376 Thymus-specific serine protease Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 241000282458 Ursus sp. Species 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 208000018839 Wilson disease Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000037919 acquired disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000001919 adrenal effect Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000002669 amniocentesis Methods 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 235000021229 appetite regulation Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- GLNDAGDHSLMOKX-UHFFFAOYSA-N coumarin 120 Chemical compound C1=C(N)C=CC2=C1OC(=O)C=C2C GLNDAGDHSLMOKX-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 description 1
- 108090000212 dipeptidyl peptidase II Proteins 0.000 description 1
- 108090000283 dipeptidyl peptidase III Proteins 0.000 description 1
- 238000012850 discrimination method Methods 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 108010072257 fibroblast activation protein alpha Proteins 0.000 description 1
- 238000005558 fluorometry Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 208000003884 gestational trophoblastic disease Diseases 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000007345 glycogen storage disease Diseases 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 208000006599 histidinemia Diseases 0.000 description 1
- 238000011905 homologation Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 210000003026 hypopharynx Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002473 insulinotropic effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002218 isotachophoresis Methods 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000005001 male reproductive tract Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000000074 matrix-assisted laser desorption--ionisation tandem time-of-flight detection Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 208000012268 mitochondrial disease Diseases 0.000 description 1
- 230000002297 mitogenic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000005962 mycosis fungoides Diseases 0.000 description 1
- 201000005987 myeloid sarcoma Diseases 0.000 description 1
- 239000006225 natural substrate Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000948 non-nucleated cell Anatomy 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 208000014380 ornithine aminotransferase deficiency Diseases 0.000 description 1
- 210000003300 oropharynx Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000012205 qualitative assay Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013074 reference sample Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 239000010979 ruby Substances 0.000 description 1
- 229910001750 ruby Inorganic materials 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 230000009450 sialylation Effects 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003741 urothelium Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- AFVLVVWMAFSXCK-UHFFFAOYSA-N α-cyano-4-hydroxycinnamic acid Chemical compound OC(=O)C(C#N)=CC1=CC=C(O)C=C1 AFVLVVWMAFSXCK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
- C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78192406P | 2006-03-13 | 2006-03-13 | |
| US80439706P | 2006-06-09 | 2006-06-09 | |
| US89276707P | 2007-03-02 | 2007-03-02 | |
| PCT/US2007/006653 WO2007106595A1 (en) | 2006-03-13 | 2007-03-13 | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2008011665A true MX2008011665A (es) | 2008-10-08 |
Family
ID=38265130
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2008011665A MX2008011665A (es) | 2006-03-13 | 2007-03-13 | Diagnóstico y pronóstico de los estados patológicos asociados a la dipeptidil-peptidasa. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8652789B2 (https=) |
| EP (1) | EP1994415B9 (https=) |
| JP (1) | JP5410955B2 (https=) |
| KR (1) | KR101376471B1 (https=) |
| CN (1) | CN101460851B (https=) |
| AU (1) | AU2007225054B2 (https=) |
| BR (1) | BRPI0708900A2 (https=) |
| CA (1) | CA2645302C (https=) |
| ES (1) | ES2549860T3 (https=) |
| MX (1) | MX2008011665A (https=) |
| WO (1) | WO2007106595A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2527649T3 (es) * | 2007-12-10 | 2015-01-28 | F. Hoffmann-La Roche Ag | Panel de marcadores para el cáncer colorrectal |
| ES2533428T3 (es) * | 2009-05-04 | 2015-04-10 | F. Hoffmann-La Roche Ag | Uso de DPPIV/Seprasa como un marcador para el cáncer |
| JP6065172B2 (ja) * | 2010-10-22 | 2017-01-25 | 国立大学法人名古屋大学 | 微小血管障害又はその関連疾患のバイオマーカー |
| US20140273008A1 (en) * | 2013-03-15 | 2014-09-18 | Molecular Bioproducts, Inc. | Methods to assess enzyme activity using mass spectrometric immunoassay |
| EP3314004A1 (en) * | 2015-06-26 | 2018-05-02 | DuPont Nutrition Biosciences ApS | Aminopeptidases for protein hydrolyzates |
| AU2017252212B2 (en) * | 2016-04-21 | 2023-09-07 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining DPP3 and therapeutic methods |
| CN110426518A (zh) * | 2019-07-19 | 2019-11-08 | 宁波熙宁检测技术有限公司 | 一种定量检测人类血浆中dpp-4酶活性的方法 |
| EP4308937B1 (en) * | 2021-03-16 | 2026-02-04 | Astrazeneca AB | System and method for online detection of a post-translational modification of a polypeptide |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4900662A (en) | 1987-07-21 | 1990-02-13 | International Immunoassay Laboratories, Inc. | CK-MM myocardial infarction immunoassay |
| US5382515A (en) | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Creative kinase-MB immunoassay for myocardial infarction and reagents |
| US5382522A (en) | 1987-07-21 | 1995-01-17 | International Immunoassay Laboratories, Inc. | Immunoassay for creatine kinase-MB and creatine kinase-BB isoforms and reagents |
| EP1631680A2 (en) * | 2003-05-21 | 2006-03-08 | Bayer HealthCare AG | Diagnostics and therapeutics for diseases associated with dipeptidylpeptidase iv (dpp4) |
| US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
-
2007
- 2007-03-13 CN CN200780016051.1A patent/CN101460851B/zh active Active
- 2007-03-13 WO PCT/US2007/006653 patent/WO2007106595A1/en not_active Ceased
- 2007-03-13 AU AU2007225054A patent/AU2007225054B2/en active Active
- 2007-03-13 JP JP2009500509A patent/JP5410955B2/ja active Active
- 2007-03-13 KR KR1020087024813A patent/KR101376471B1/ko active Active
- 2007-03-13 EP EP07753293.5A patent/EP1994415B9/en not_active Not-in-force
- 2007-03-13 ES ES07753293.5T patent/ES2549860T3/es active Active
- 2007-03-13 US US11/724,029 patent/US8652789B2/en active Active
- 2007-03-13 BR BRPI0708900-7A patent/BRPI0708900A2/pt not_active Application Discontinuation
- 2007-03-13 CA CA2645302A patent/CA2645302C/en active Active
- 2007-03-13 MX MX2008011665A patent/MX2008011665A/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009529884A (ja) | 2009-08-27 |
| AU2007225054A1 (en) | 2007-09-20 |
| CA2645302A1 (en) | 2007-09-20 |
| US8652789B2 (en) | 2014-02-18 |
| EP1994415B9 (en) | 2015-12-16 |
| ES2549860T3 (es) | 2015-11-02 |
| KR101376471B1 (ko) | 2014-03-27 |
| CA2645302C (en) | 2017-07-11 |
| JP5410955B2 (ja) | 2014-02-05 |
| CN101460851B (zh) | 2016-09-21 |
| EP1994415B1 (en) | 2015-07-29 |
| WO2007106595A1 (en) | 2007-09-20 |
| AU2007225054B2 (en) | 2012-08-16 |
| KR20090008218A (ko) | 2009-01-21 |
| EP1994415A1 (en) | 2008-11-26 |
| US20070264671A1 (en) | 2007-11-15 |
| CN101460851A (zh) | 2009-06-17 |
| BRPI0708900A2 (pt) | 2011-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8652789B2 (en) | Diagnosis and prognosis of dipeptidyl peptidase-associated disease states | |
| Lahiri et al. | Systemic inflammatory response syndrome after major abdominal surgery predicted by early upregulation of TLR4 and TLR5 | |
| Esteghamat et al. | CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation | |
| Banne et al. | Reduced level of serum thiols in patients with a diagnosis of active disease | |
| Grobe et al. | Identification of prolyl carboxypeptidase as an alternative enzyme for processing of renal angiotensin II using mass spectrometry | |
| Posadas-Sanchez et al. | Dipeptidylpeptidase-4 levels and DPP4 gene polymorphisms in patients with COVID-19. Association with disease and with severity | |
| Yang et al. | 5-Hydroxymethylcytosines in circulating cell-free DNA reveal vascular complications of type 2 diabetes | |
| ATE290210T1 (de) | Verwendung von antikörpern gegen embryonales hämoglobin zur identifizierung von fötalen zellen | |
| König et al. | The serum protease network—one key to understand complex regional pain syndrome pathophysiology | |
| Byzia et al. | Activity profiling of aminopeptidases in cell lysates using a fluorogenic substrate library | |
| JP6081912B2 (ja) | ｃ−Ｓｒｃ選択反応モニタリングアッセイ | |
| Koh et al. | Single cell transcriptomes derived from human cervical and uterine tissue during pregnancy | |
| Saadi et al. | Predictors of successful outcome after adrenalectomy for unilateral primary aldosteronism | |
| RU2000119129A (ru) | Молекула днк, кодирующая мутантный препронейропептид y, мутантный сигнальный пептид и их применения | |
| US20190316202A1 (en) | Dna methylation in inflammatory disease | |
| Crookston et al. | False negative factor V Leiden assay following allogeneic stem cell transplant | |
| Seefeld et al. | Parallel assessment of circulatory cell-free DNA by PCR and nucleosomes by ELISA in breast tumors | |
| EP3170001B1 (en) | Viability assessment of in vitro cultured embryos from the culture medium | |
| Shenoy et al. | Lipid-bound sialic acid in psoriasis and its correlation with disease severity | |
| JP7328950B2 (ja) | 乳幼児アトピー性皮膚炎の検出方法 | |
| US7759086B2 (en) | Diagnostic method for chronic fatigue syndrome by measuring elastase | |
| Kalpidis | Role of Salivary Biomarkers in Diagnosis and Monitoring of Patients with Autoimmune Diseases: A Systematic Review | |
| Smith et al. | Performance Comparison of RaDaR 1.0 and RaDaR ST Assays for Circulating Tumor DNA Detection Across Solid Tumor Types | |
| WO2013011513A9 (en) | Methods of determining enzyme activity in preserved cell samples | |
| Manjunath Shenoy | Lipid-bound sialic acid in psoriasis and its correlation with disease severity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |